Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart insulin pump may boost brain and body health in older adults with diabetes

NCT ID NCT06236256

Disease control Sponsor: Sheba Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether an advanced hybrid closed loop insulin pump (MiniMed 780G) can improve blood sugar control, quality of life, thinking skills, and physical abilities in people over 60 with type 1 diabetes. Participants are randomly assigned to either continue their usual insulin therapy or use the automated system for 12 months. The goal is to see if this technology offers extra benefits beyond standard care for older adults.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MiniMed 780G advanced hybrid closed loop insulin pump system
What this could lead to
If successful, this could show that automated insulin delivery improves not only blood sugar control but also physical function, thinking skills, and quality of life in older adults with type 1 diabetes.
What could go wrong
This is a small, early-stage trial with only 42 participants, so results may not apply to everyone. The device requires consistent use and may not work equally well for all individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

Jan 2024

Finished

Aug 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age over 60 years 2. T1DM 3. Willing to participate in a study for the specified duration 4. Willing to perform ≥ 4 finger stick blood glucose measurements daily or connected to a "basket approved" CGM 5. Willing to wear the system continuously throughout the study 6. Treated with MDI/CSII (with exclusion of 780G or other hybrid closed systems) 7. Lack of advanced complications of diabetes Exclusion Criteria: 1. Severe concurrent illness 2. Laboratory abnormalities, or medications that might affect study participation, 3. Severe renal impairment 4. Any illness that may interfere with study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 1

Contacts and locations

Locations

  • Sheba medical center

    Ramat Gan, Israel, 52621, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.